Abstract: Optically isotropic, thermodynamically and chemically stable microemulsions of antimicrobials comprising of mixtures of N-undecylenoyl glycine, N-capryloyl glycine and 2-phenoxy ethanol for preservation of personal care products are described herein. They offer a broad spectrum of antimicrobial activity by inhibiting the growth of bacteria as well as fungi that can otherwise flourish in personal care products rendering them unsuitable for the use. The personal care products that can be preserved by these microemulsions of antimicrobials are, gels, serums, solutions, lotions, creams, emulsions, wet wipes and the like, containing water in varying amount.

Abstract: A wound healing composition and method for wound healing utilizing a nitrofurazone in a water soluble ointment, activated charcoal, caustic and biebrich scarlet. Applying the composition to the wound and observing epithelial healing along the sides and bottom of the wound. Stopping treatment when the epithelial tissue fills the wound.

Abstract: The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.

Abstract: The invention relates to an oily composition of a non-steroidal anti-inflammatory agent (NSAIA) for parenteral administration with at least one micronized NSAIA, having an acid function and a biocompatible oily vehicle, such that said NSAIA is in the form of a free acid and said composition does not contain any added liquid agent that can solubilize said NSAIA. The invention also relates to the veterinary use thereof.

Abstract: An apparatus and method for providing cosmetic treatment to skin comprise one material chemically active in a solid form preferably in a tablet form and a second material which is chemically reactive with the first material so that effervescence is produced during the reaction. The chemically active materials may be activated by a user for providing cosmetic treatment to skin. The activation releases effervescence which urges granules of the reacting materials onto the skin. The size of the granules lowers during the reaction thus providing continuously refining peeling to the skin.

Abstract: The invention provides a pharmaceutical composition for the transmucosal delivery of a statin, said composition comprising a statin and a carrier in which said statin is soluble or forms a suspension or emulsion. The invention also provides a pharmaceutical composition comprising a statin for use in inhibiting cholesterol synthesis in vivo, where in said use said composition is delivered by the transmucosal route.

Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

Abstract: The present patent application relates to a pharmaceutical composition, characterized in that it comprises at least one active ingredient which can bring about a singlet oxygen-independent direct catalase inactivation and that the composition further comprises at least one active ingredient that leads to inactivation of catalase as a result of modulation of the nitrogen oxide or superoxide anion metabolism of the cells and subsequent singlet oxygen formation.

Abstract: The present invention relates a foamable otic pharmaceutical compositions comprising oil-in water emulsions which comprise an antibiotic agent and a propellant gas. The pharmaceutical compositions are administered to the ear as foam for treating ear disorders.

Abstract: Disclosed is a pH-stabilized oral tobacco composition comprising a buffer of at least two pH stabilizing substances comprising potassium carbonate and at least one additional pH stabilizing substance that can maintain a low total drop in pH-value over prolonged time at ambient as well as refrigerated temperature, so that the freshness and shelf life of the oral tobacco composition can be improved.

Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Abstract: The present invention provides a safe, disposable and biodegradable chlorine dioxide micro generator that uses water soluble paper and hydrogel or compressed cellulose encased in filter paper pouch. The chemicals are kept in a stabilize form until activated by the addition of water. Multiple levels of protection against early exposure to water such as a foil pouch and an impermeable outer container allow for the safe transportation and storage in small, ready for deployment amounts of the chemicals. Water permeated the chemical pack housing and dissolves the paper walls of the chemical pouch housing and then the water facilitates the reaction between the acid and the sodium chlorite to form chlorine dioxide gas as will be described further hereunder. Absorbent and permeable materials packaged around the chemicals provide for the safe containment of the chlorine dioxide solution, and the expeditious aeration and release of the chlorine dioxide gas, once the chemical reaction has been completed.

Abstract: Use of glyceryl trinitrate (GTN) for treating traumatic edemas.

Abstract: The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated. The present invention provides a medical aerosol formulation comprising a particular medicament, a fluorocarbon propellant and 6 to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant. Canisters suitable for delivering such a pharmaceutical formulation are also provided.

Abstract: A method for killing insects, involving treating an object or area with an insect killing effective amount of a composition containing methyl benzoate and optionally a carrier.

Abstract: The invention provides a method of ameliorating inflammation in a patient involving administering to the patient a therapeutically effective dose of composition including polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer. More particularly, the method relates to using these polymers as an enteral sorbent preparation to remove inflammatory mediators, such as cytokines, from the intestinal lumen. The polymers can be in the form of a preparation of polystyrene divinyl benzene copolymer beads with a biocompatible polyvinyl pyrrolidone polymer coating.

Abstract: A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.

Abstract: Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Abstract: The present invention relates to pharmaceutical compositions and in particular to suspension aerosol pharmaceutical compositions, processes to obtain them and their use in inhalation therapy.

Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

Abstract: The process for preparing 2-hydroxyphenyl alkenyl benzotriazole compounds and the process for preparing siloxane compounds containing 2-hydroxyphenyl benzotriazole function are disclosed.

Abstract: This invention relates to a composition and its use for formulating nucleic acid-based drugs/vaccines with sugar alcohol compositions into complexes for both in-vitro and in-vivo delivery. Particularly, the present invention includes the ingredients and processes necessary for formulating therapeutic and pharmaceutical nucleic acid compositions, such as miRNA, microRNA precursors, shRNAs, siRNAs, ribozymes, antisense RNAs/DNAs, RNA-DNA hybrids and DNA vectors/vaccines, with glycylated sugar alcohols/sugars into delivery complexes, which can then be absorbed by cells in vivo and in vitro via active endocytosis. Also, the present invention discloses that chemical compounds containing sugar alcohol- and/or sugar-like structures can protect nucleic acids, in particular miRNAs, shRNAs, siRNAs and ribozymes, from degradation in vivo as well as in vitro.

Abstract: The invention provides compositions and methods for the improvement of distance vision. The invention further provides compositions and methods for the treatment of refractive errors of the eye. The invention further provides compositions that preferably comprise aceclidine lyophilized with a cryoprecipitate separate or together with a diluent comprising a cycloplegic agent, a surfactant, and optionally a viscosity enhancer.

Abstract: Low-temperature stable concentrate compositions comprising an acyl glycinate present in an amount greater than 70 wt % by weight of the composition; and b) at least one of a zwitterionic surfactant or an amphoteric surfactant present in an amount greater than 0.1 wt % by weight of the composition, wherein the concentrate is low temperature stable.

Abstract: A process for preparing a siloxane compound comprising a 2-hydroxyphenyl benzotriazole function which comprises at least one step in which a reaction for hydrosilylation of a compound 2-hydroxyphenyl benzotriazole comprising a substituent having a terminal double bond with a siloxane compound comprising an SiH function is carried out in the presence of a catalyst and of at least one volatile organic solvent corresponding to one of formula (VII) or (VIII). in which R4 and R5, which may be identical or different, represent a linear or branched C1-C4 alkyl radical, with the proviso that the sum of the carbons of R4 and R5 is less than or equal to 6; y is and integer between 1 and 3; R6 which may be identical or different, are linear or branched C1-C3 alkyl radicals, with the proviso that the sum of the carbons of R6 is less than or equal to 6 is disclosed.

Abstract: A pumpable liquid spray formulation for retarding degradation of color cosmetics, the pumpable liquid spray formulation being characterized by: the presence of at least one encapsulated evaporative cooling agent; and at least one entrained solvent; and the absence of fluorocarbon-based evaporative cooling agents, whereby the reduction of the surface temperature of the color cosmetics is achieved by a controlled release of the entrained solvents by the at least one encapsulated evaporative cooling agent.

Abstract: The invention relates to an oral pharmaceutical composition comprising the combination of an ibuprofen salt or S(+)-ibuprofen with L-arginine and/or the pharmaceutically acceptable salts thereof, and additionally pharmaceutically acceptable vehicles and/or excipients. The invention also relates to the method of producing the composition and to the use of said composition having synergic therapeutic activity, for treating moderate to severe inflammatory pain, fever and inflammation.

Abstract: A chewable tablet comprising Cefixime having a mean particle size between 20? and 120? wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20? and 120?, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets.

Abstract: Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis.

Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

Abstract: Methods and compositions are described for reducing airway reactivity and the susceptibility to asthmatic bronchoconstriction that involve increasing sphingolipid content in airways and lungs of a mammalian subject.

Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Abstract: The invention relates to effervescent pharmaceutical dosage forms including cefdinir as the active agent, and their preparation. The invention also relates to effervescent formulations including ceftibuten and/or its pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof. The invention also relates to pharmaceutical compositions including (Z)-3-Carboxymethyl-7-(2-(2-furyl)-2-methoxyiminoacetylamino)-3-sefem-4-carboxylic acid which is named cefuroxime axetil or any pharmaceutically acceptable derivative thereof, and the use of these compositions in the treatment of bacterial infections. Lastly, the invention relates to pharmaceutical formulations including a third generation cephalosporin together with clavulanic acid and/or derivatives thereof as the active agents.

Abstract: A pesticidal composition comprising 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether; a hydrophobic organic solvent capable of dissolving 0.1-fold by weight of 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether at 0° C.; polyvinyl alcohol; a nonionic surfactant selected from the group consisting of alkoxylated castor oil, alkoxylated hydrogenated castor oil and alkoxylated hydrogenated castor oil fatty acid ester; and water, is excellent in storage stability.

Abstract: A composition comprising iron pyrophosphate and copper citrate does not exhibit the unpleasant taste and aftertaste usually found with iron supplements.

Abstract: The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.

Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurized metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.

Abstract: The invention relates to an aerosol device containing a cosmetic composition comprising: (i) from 0.1% to 15% by weight relative to the total weight of the composition, of one or more water-insoluble calcium salts, (ii) one or more fixing polymers, (iii) one or more C2-4 monoalcohols, and (iv) one or more propellants. The invention also relates to a process for shaping the hair and/or for holding the hairstyle, using the aerosol device of the invention.

Abstract: The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%;or about 10% to about 20%; or about 20% to about 50% by weight; about 0.1% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and (5) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: A freshening composition having a malodor control component, about 1% to about 5% of low molecular weight monohydric alcohols, and an aqueous carrier are provided. The composition is essentially free of any material that would soil or stain fabric. The composition may be delivered to fabrics and/or air. The malodor control component may include an effective amount of volatile aldehydes and/or an acid catalyst.

Abstract: The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis, as well as for prophylactic and/or cosmetic purposes.

Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.

Abstract: Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.

Abstract: Hair care and styling compositions that can provide shine, frizz control and temporary styling benefits. More specifically, it relates to hair treatment compositions that comprise of viscoelastic particles in an aqueous carrier or a mixture of water with organic or silicone carrier.

Abstract: An oil in water emulsion that has a water phase and an oil phase. The water phase includes greater than about 0.5% of the salt form of a neutralized acid, the acid being preferably salicylic acid; and, from about 2% to about 0.001%, by weight of a gum. The oil in water emulsion is stable, that is, it is substantially unaltered in chemical state and physical homogeneity, upon exposure to 14 days at a temperature & humidity of about 50° C. and 60% RH. The gum is preferably xanthan gum, and the emulsion may include from about 0.01 to about 10%, of an emulsifier.

Abstract: The present invention provides materials and methods for inducing ion secretion and/or for treating cystic fibrosis. In one embodiment, the composition comprises glucose and/or a non-metabolizable glucose analog and/or non-structural protein (NSP4), a NSP4 peptide, or a NSP4 toxoid as the active ingredient, formulated with pharmaceutically-acceptable carriers. In a preferred embodiment, the composition is in a form of an aerosol preparation for intranasal and/or pulmonary administration, and is used to stimulate chloride and fluid secretion in nasal, tracheal and/or bronchial epithelium.

Abstract: Aerosolized dapsone (or alternatively, an aqueous formulation of dapsone) is used to treat airway inflammation, particularly chronic neutrophil-dominated inflammation. Diseases that may be prevented or treated by the methods include chronic obstructive pulmonary diseases (COPDs), asthma, cystic fibrosis, and others.

Abstract: There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.

Abstract: An antiperspirant composition comprising a suspension of from 1 to 50% of an aluminium and/or zirconium containing antiperspirant active, a carrier substance in which the antiperspirant active is insoluble, and a poly(ethylene glycol) solution of a polyelectrolyte salt comprising sodium, potassium, magnesium, calcium, chloride and bromide ions, the weight ratio of sodium to the other named cations being less than 3:2 and the weight ratio of the bromide to chloride anion being greater than 1:99, in said solution.